Literature DB >> 19695027

What is left ventricular hypertrophy and is there a reason to regress left ventricular hypertrophy?

Matthew R Weir1, Raymond R Townsend.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19695027      PMCID： PMC8673142          DOI： 10.1111/j.1751-7176.2009.00156.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  23 in total

Review 1.  Arterial stiffness.

Authors:  M F O'Rourke; G Mancia
Journal:  J Hypertens       Date:  1999-01       Impact factor: 4.844

2.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

Review 3.  Importance of arterial stiffness as cardiovascular risk factor for future development of new type of drugs.

Authors:  Pierre Boutouyrie; Stéphane Laurent; Marie Briet
Journal:  Fundam Clin Pharmacol       Date:  2008-06       Impact factor: 2.748

4.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

5.  Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community.

Authors:  A P Avolio; S G Chen; R P Wang; C L Zhang; M F Li; M F O'Rourke
Journal:  Circulation       Date:  1983-07       Impact factor: 29.690

6.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

7.  Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension.

Authors:  P Verdecchia; C Porcellati; G Reboldi; R Gattobigio; C Borgioni; T A Pearson; G Ambrosio
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

8.  Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study.

Authors:  Mark H Drazner; J Eduardo Rame; Emily K Marino; John S Gottdiener; Dalane W Kitzman; Julius M Gardin; Teri A Manolio; Daniel L Dries; David S Siscovick
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

Review 9.  Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy.

Authors:  N Westerhof; M F O'Rourke
Journal:  J Hypertens       Date:  1995-09       Impact factor: 4.844

Review 10.  Mechanical factors in arterial aging: a clinical perspective.

Authors:  Michael F O'Rourke; Junichiro Hashimoto
Journal:  J Am Coll Cardiol       Date:  2007-06-18       Impact factor: 24.094
View more
  1 in total

1.  Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.

Authors:  George C Roush; Ramy Abdelfattah; Steven Song; Michael E Ernst; Domenic A Sica; John B Kostis
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-09-24       Impact factor: 3.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.